Biocon Share Price in Focus After Q2 FY26 Results Show ₹84 Crore Profit Turnaround

Biocon Limited shares are expected to stay in focus on Wednesday, November 12, 2025, after the company reported a strong turnaround in its second-quarter results. 

The Bengaluru-based biopharmaceutical firm posted a consolidated net profit of ₹84.5 crore for Q2 FY26, compared with a loss of ₹16 crore in the same period last year, supported by improved margins and higher segmental contributions.

Biocon Q2 FY26 Financial Performance

Biocon’s operating revenue for the quarter rose 20% year-on-year (YoY) to ₹4,296 crore, while consolidated revenue stood at ₹4,389 crore, reflecting a 21% increase.

The company’s EBITDA climbed 29% to ₹928 crore, with margins expanding to 21%, signalling enhanced operational efficiency.

Core EBITDA rose 23% to ₹1,218 crore, translating into a 28% margin, while profit before tax (before exceptional items) surged 153% YoY to ₹183 crore.

Research and Development

Net R&D investments amounted to ₹251 crore, accounting for 7% of revenue (excluding Syngene). 

This continued investment underlines Biocon’s focus on advancing its biosimilars and generics pipeline across global markets.

Segmental Highlights

• Biosimilars: Revenue rose 25% YoY to ₹2,721 crore, maintaining its position as the largest contributor to the business.
• Generics: Posted ₹774 crore, up 24% YoY, supported by steady demand and new product introductions.
• CRDMO (Syngene): Recorded ₹911 crore, a modest 2% YoY rise amid stable performance.

For Q2 FY26, segmental revenue contribution stood at 61% from Biosimilars, 21% from CRDMO, and 18% from Generics.

Biocon Share Price Performance

Biocon Limited shares traded at ₹384.25, down ₹0.85 or 0.22% from the previous close of ₹385.10 on the BSE.

Read More: BSE Share Price in Focus After Q2 FY26 Results Show 61% YoY Rise in Net Profit.

Conclusion

Biocon’s return to profitability in Q2 FY26 marks a key milestone in its financial recovery, supported by strong performance in biosimilars and improved cost management.

With debt reduction measures and stable segmental growth, the company appears positioned for sustained earnings momentum in the coming quarters.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.